A Randomised, Double-Blind, Placebo-Controlled Study of a Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) of a FimH Antagonist, EB8018, in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 05 Jan 2017
At a glance
- Drugs EB 8018 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man
- Sponsors Enterome
- 05 Jan 2017 According to an Enterome media release, the company anticipates to report the results from this study later in 2017.
- 22 Apr 2016 As per Enterome Bioscience media release, this trial is anticipitated to start during 2016.
- 22 Apr 2016 New trial record